secwatch.observer — SEC 8-K summary
======================================

Issuer:     Odyssey Health, Inc. (ODYY)
CIK:        0001626644
Form:       8-K
Filed at:   2022-11-25T23:59:59+00:00
Accession:  0001683168-22-008034
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Odyssey Health provides update on concussion drug program; Phase I trial completed, safety shown
--------------------------------------------------------------------------------

- Completed FDA-required Phase I human clinical trial; drug safe, well tolerated, no accumulation over 10 days.
- Raised over $5M in funding; access to Lincoln Park equity line of up to $10M.
- Added two key executives with pharmaceutical drug development experience to management.
- Filed patent application for novel breath-propelled intranasal delivery device.
- Developed nanoparticle spray-dried formulation in partnership with UK partner under GMP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822008034/0001683168-22-008034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626644/000168316822008034/odyssey_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-008034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer